Circulating tumor cells in hepatocellular carcinoma: a pilot study of detection, enumeration, and next-generation sequencing in cases and controls

Table 1 Patient characteristics

	HCC cohort (n = 20)	NMLD control Cohort (n = 10)
Median age (range) (years)	61.5 (50–82)	26-91 (53.5)
Male/female (n)	20/0	9/1
Etiology of liver disease (%)
HBV	25	20
HCV	45	60
Co-infection HBV + HCV^a	10	0
ETOH	5	10
NAFLD	10	0
PSC	0	10
Unknown	5	0
Race/ethnicity (%)
African-American	5	10
Asian	35	10
Caucasian	55	70
Hispanic/Latino	5	30
Non-Hispanic/Latino	50	40
Native American	5	0
Other/unknown	0	10
Child Pugh score (%)
A/B/C/unknown	70/25/5/0	30/30/30/10
Median AFP (range) (ng/mL)	492 (3.8-587,134)	5.5 (1.7-17.2)
BCLC score C (%)^b	100	N/A
Vascular invasion (%)	65	N/A
Extrahepatic spread (%)^b	100	N/A
Median overall survival (months)	9.4 months	Not measured

Key: HBV = hepatitis B virus. HCV = hepatitis C virus. ETOH = alcohol. NAFLD = non-alcoholic fatty liver disease. PSC = primary sclerosing cholangitis. BCLC = Barcelona Clinic Liver Cancer. N/A = not applicable.
^aDefined as HCV antibody positive plus either HBV surface antigen and/or core antibody positive.
^bBCLC C and presence of extrahepatic spread were required eligibility criteria for HCC cohort.

ISSN: 1471-2407